Alterity therapeutics ltd - adr
ATHE 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分中等，已經有部位可以持續持有，若想建立新部位可以等待價值評分轉變為4分以上、股利提升為2分以上
ATHE 近期報酬表現
-4.56%
Alterity therapeutics ltd - adr
-0.10%
同產業平均
-1.57%
S&P500
與 ATHE 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
INTS | Intensity therapeutics inc | - | 2 分 | 2 分 | 1 分 | 1 分 | |
EYPT | Eyepoint pharmaceuticals inc | 3 分 | 2 分 | 2 分 | 3 分 | 1 分 | |
DERM | Journey medical corp | - | 2 分 | 2 分 | 1 分 | 1 分 | |
CERE | Cerevel therapeutics holdings inc | 3 分 | 4 分 | 2 分 | 4 分 | 1 分 | |
SYRS | Syros pharmaceuticals inc | 4 分 | 2 分 | 2 分 | 2 分 | 1 分 |
- INTS Intensity therapeutics inc價值 -趨勢 2 分波段 2 分籌碼 1 分股利 1 分查看更多
ATHE 公司資訊
Alterity Therapeutics Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing disease modifying treatments for neurodegenerative diseases. The Company's lead asset, ATH434, is to treat various Parkinsonian disorders. ATH434 is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. It has the potential to treat Parkinson's disease, as well as various Parkinsonian disorders, such as Multiple System Atrophy (MSA). The Company also has a drug discovery platform generating patentable chemical compounds to intercede in disease processes. ATH434 has been granted Orphan designation for the treatment of MSA. The Phase 2 clinical trial is a randomized, double-blind, placebo-controlled investigation of ATH434 in patients with early-stage MSA.